Monica Venere

Dr. Monica Venere


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2016 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JDJosephine Kam Tai Dermawan
Josephine Kam Tai Dermawan
MHMasahiro Hitomi
Masahiro Hitomi
DSDaniel J. Silver
Daniel J. Silver
QWQiulian Wu
Qiulian Wu
PSPoorva Sandlesh
Poorva Sandlesh
MVMonica Venere
Monica Venere
The nearly universal recurrence of glioblastoma (GBM) is driven in part by a treatment-resistant subpopulation of GBM stem cells (GSC). To identify improved therapeutic possibilities, we combined the EGFR/HER2 inhibitor lapatinib with a novel small molecule, CBL0137, which inhibits FACT (facilitates chromatin transcription), a histone chaperone complex predominantly expressed in undifferentiated cells. Lapatinib and CBL0137 synergistically inhibited the proliferation of patient-derived GBM cells. Compared with non–stem tumor cells (NSTC) enriched from the same specimens, the GSCs were extremely sensitive to CBL0137 monotherapy or FACT knockdown. FACT expression was elevated in GSCs compared with matched NSTCs and decreased in GSCs upon differentiation. Acute exposure of GSCs to CBL0137 increased asymmetric cell division, decreased GSC marker expression, and decreased the capacity of GSCs to form tumor spheres in vitro and to initiate tumors in vivo. Oral administration of CBL0137 to mice bearing orthotopic GBM prolonged their survival. Knockdown of FACT reduced the expression of genes encoding several core stem cell transcription factors (SOX2, OCT4, NANOG, and OLIG2), and FACT occupied the promoters of these genes. FACT expression was elevated in GBM tumors compared with non-neoplastic brain tissues, portended a worse prognosis, and positively correlated with GSC markers and stem cell gene expression signatures. Preferential targeting of GSCs by CBL0137 and synergy with EGFR inhibitors support the development of clinical trials combining these two agents in GBM. Cancer Res; 76(8); 2432–42. ©2016 AACR.

22 December 2018 in Neuro-Oncology
Verified
Journal Article
Open access
JTJennie W Taylor
Jennie W Taylor
TATerri Armstrong
Terri Armstrong
AKAlbert H. Kim
Albert H. Kim
MVMonica Venere
Monica Venere
AAAlvina Acquaye
Alvina Acquaye
PWPatrick Y Wen
Patrick Y Wen

29 April 2019 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
KDKuntal De
Kuntal De
TGTreg M. Grubb
Treg M. Grubb
AZAbigail A. Zalenski
Abigail A. Zalenski
KPKayla E. Pfaff
Kayla E. Pfaff
DPDebjani Pal
Debjani Pal
MVMonica Venere
Monica Venere
Glioblastoma (GBM) is the most common and lethal primary brain tumor and remains incurable. This is in part due to the cellular heterogeneity within these tumors, which includes a subpopulation of treatment-resistant cells called cancer stem–like cells (CSC). We previously identified that the anaphase-promoting complex/cylosome (APC/C), a key cell-cycle regulator and tumor suppressor, had attenuated ligase activity in CSCs. Here, we assessed the mechanism of reduced activity, as well as the efficacy of pharmacologically targeting the APC/C in CSCs. We identified hyperphosphorylation of CDH1, but not pseudosubstrate inhibition by early mitotic inhibitor 1 (EMI1), as a major mechanism driving attenuated APC/CCDH1 activity in the G1-phase of the cell cycle in CSCs. Small-molecule inhibition of the APC/C reduced viability of both CSCs and nonstem tumor cells (NSTCs), with the combination of proTAME and apcin having the biggest impact. Combinatorial drug treatment also led to the greatest mitotic arrest and chromosomal abnormalities. Implications: Our findings demonstrate how the activity of the APC/CCDH1 tumor suppressor is reduced in CSCs and also validates small-molecule inhibition of the APC/C as a promising therapeutic target for the treatment of GBM.

2 August 2022 in Communications Biology
Verified
Journal Article
Open access
PDF file
LBLauren Broestl
Lauren Broestl
NWNicole M. Warrington
Nicole M. Warrington
LGLucia Grandison
Lucia Grandison
TATamara Abou-Antoun
Tamara Abou-Antoun
OTOlivia Tung
Olivia Tung
JRJoshua B. Rubin
Joshua B. Rubin
Males exhibit higher incidence and worse prognosis for the majority of cancers, including glioblastoma (GBM). Disparate survival may be related to sex-biased responses to treatment, including radiation. Using a mouse model of GBM, we show that female cells are more sensitive to radiation, and that senescence represents a major component of the radiation therapeutic response in both sexes. Correlation analyses revealed that the CDK inhibitor p21 and irradiation induced senescence were differentially regulated between male and female cells. Indeed, female cellular senescence was more sensitive to changes in p21 levels, a finding that was observed in wildtype and transformed murine astrocytes, as well as patient-derived GBM cell lines. Using a novel Four Core Genotypes model of GBM, we further show that sex differences in p21-induced senescence are patterned during early development by gonadal sex. These data provide a rationale for the further study of sex differences in radiation response and how senescence might be enhanced for radiation sensitization. The determination that p21 and gonadal sex are required for sex differences in radiation response will serve as a foundation for these future mechanistic studies.

24 March 2019 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
KPKyoung‐Joo J. Park
Kyoung‐Joo J. Park
JKJames Kim
James Kim
TTThomas Testoff
Thomas Testoff
JAJoseph Adams
Joseph Adams
MPMiranda Poklar
Miranda Poklar
Jeffrey chalmersJeffrey chalmers
Jeffrey chalmers

1 February 2021 in Cancer Letters
Verified
Journal Article
Open access
MTMiranda M. Tallman
Miranda M. Tallman
AZAbigail A. Zalenski
Abigail A. Zalenski
ADAmanda M. Deighen
Amanda M. Deighen
MSMorgan S. Schrock
Morgan S. Schrock
SMSherry Mortach
Sherry Mortach
MVMonica Venere
Monica Venere
Glioblastoma (GBM) is an incurable brain tumor with inevitable recurrence. This is in part due to a highly malignant cancer stem cell (CSC) subpopulation of tumor cells that is particularly resistant to conventional treatments, including radiotherapy. Here we show that CBL0137, a small molecule anti-cancer agent, sensitizes GBM CSCs to radiotherapy. CBL0137 sequesters the FACT (facilitates chromatin transcription) complex to chromatin, resulting in cytotoxicity preferentially within tumor cells. We show that when combined with radiotherapy, CBL0137 inhibited GBM CSC growth and resulted in more DNA damage in the CSCs compared to irradiation or drug alone. Using an in vivo subcutaneous model, we showed that the frequency of GBM CSCs was reduced when tumors were pretreated with CBL0137 and then exposed to irradiation. Survival studies with orthotopic GBM models resulted in significantly extended survival for mice treated with combinatorial therapy. As GBM CSCs contribute to the inevitable recurrence in patients, targeting them is imperative. This work establishes a new treatment paradigm for GBM that sensitizes CSCs to irradiation and may ultimately reduce tumor recurrence.